- Home
- INV vs KOD Comparison
INV vs KOD Comparison
Compare INV & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INV
- KOD
- Stock Information
- Founded
- INV 2015
- KOD 2009
- Country
- INV United States
- KOD United States
- Employees
- INV N/A
- KOD N/A
- Industry
- INV
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INV
- KOD Health Care
- Exchange
- INV NYSE
- KOD Nasdaq
- Market Cap
- INV 173.3M
- KOD 198.4M
- IPO Year
- INV N/A
- KOD 2018
- Fundamental
- Price
- INV $4.65
- KOD $4.38
- Analyst Decision
- INV Strong Buy
- KOD Hold
- Analyst Count
- INV 2
- KOD 3
- Target Price
- INV $14.00
- KOD $9.00
- AVG Volume (30 Days)
- INV 171.5K
- KOD 301.5K
- Earning Date
- INV 08-15-2025
- KOD 08-13-2025
- Dividend Yield
- INV N/A
- KOD N/A
- EPS Growth
- INV N/A
- KOD N/A
- EPS
- INV N/A
- KOD N/A
- Revenue
- INV $1,220,000.00
- KOD N/A
- Revenue This Year
- INV $1,045.66
- KOD N/A
- Revenue Next Year
- INV $240.46
- KOD N/A
- P/E Ratio
- INV N/A
- KOD N/A
- Revenue Growth
- INV 18.27
- KOD N/A
- 52 Week Low
- INV $3.00
- KOD $1.92
- 52 Week High
- INV $18.75
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- INV N/A
- KOD 65.72
- Support Level
- INV N/A
- KOD $3.70
- Resistance Level
- INV N/A
- KOD $4.01
- Average True Range (ATR)
- INV 0.00
- KOD 0.25
- MACD
- INV 0.00
- KOD 0.08
- Stochastic Oscillator
- INV 0.00
- KOD 97.70
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.